Skip to content

Treatment of Atrophic Post Acne Scars by Fat Grafting

Autologous Fat Cells Transfer for the Treatment of Atrophic Post Acne Scars: Clinical Trail

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05028283
Enrollment
69
Registered
2021-08-31
Start date
2021-08-19
Completion date
2023-10-20
Last updated
2023-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic Acne Scars

Keywords

Acne- atrophic scars - autologous fat

Brief summary

This single-center, clinical trial consists of a one autologous fat grafting treatment followed by1-week , 1month , 3-month and 6-month post-treatment visits in order to assess the efficacy and complications of fat grafting when used for facial atrophic acne scars on cheeks.

Detailed description

This investigation, pilot study will evaluate the safety and efficacy of autologous fat grafting for the treatment of atrophic acne scarring on cheeks. Overall assessment of clinical outcome and safety will be based clinic visits and evaluation of pre- and post- procedural on the Goodman-Barron scale. The subject's assessment of satisfaction will be characterized using a non-parametric assessment scale at the end of the follow-up period.

Interventions

PROCEDUREFat Grafting

This single-center, clinical trial will assess the efficacy and tolerability of the autologous fat grafting when used on men and women with atrophic acne scars on the cheeks

Sponsors

Damascus University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with atrophic post acne scars on the cheeks, between 20 - 40 years old * Not to apply other treatments a month before the procedure * Informed consent to enter the study

Exclusion criteria

* First grade of Goodman - Barron scale. * A systemic or associated skin disease that may affect the results of the study * patients with chronic consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) or other non-aggregating agents. * Patients with acne in the acute stage * Pregnancy and breastfeeding * Tendency to form keloids

Design outcomes

Primary

MeasureTime frameDescription
• Change in atrophic acne scars assessmentBaseline and 6 MonthsAcne scars will be used to evaluate efficacy of treatment using the Goodman- Barron scale \[which is an acne scars severity scale divided into 4 grades * First grade consists of hyper-or hypopigmented flat marks * Second grade consists of mild atrophy or hypertrophy that may not be obvious at social distances of 50 cm or greater and may be covered adequately by makeup * Third grade consists of moderate atrophic or hypertrophic scarring that is obvious at social distances of 50 cm or greater and is not covered easily by makeup or the normal shadow * Fourth grade severe atrophic or hypertrophic scarring that is obvious at social distances of 50 cm or greater and is not covered easily by makeup or the normal shadow\]. The grade of acne scars from final visit will be compared to their baseline grade visually evaluated by the study team.
Change in patient satisfaction3 Months, and 6 MonthsThe modified global aesthetic improvement scale for patient evaluation module which consists of 5 degrees * Exceptionally improved \[The ideal result has been achieve\] * much improved\[The result is much improved but suboptimal\] * Improved\[The result is improved but an additional procedure is recommended \] * no difference\[The result is the same when compared with the preoperative state\] * Worse\[The result is worse when compared with the preoperative state\] This module will be administered 3monts and 6 months postoperatively to analyze satisfaction and aesthetic perception of the result.

Secondary

MeasureTime frameDescription
Change in Erythema PresenceBaseline ,1 week ,1 month,3 months and 6 MonthsPatients will be examined after procedure to check erythema presence and will be monitored until it will disappear
Change in Infection existence1 week, 1 month, 3 months and 6 MonthsPatients will be examined after procedure to check existence of infection and will be monitored until it will heal.
Change in Irregularity PresenceBaseline and 6 MonthsPatients will be examined after procedure to check irregularity presence at the end of the study
Change in Swelling StatusBaseline ,1 week 1month,3 months and 6 MonthsPatients will be examined after procedure to check swelling status and will be monitored until it will disappear
Change in Bruising StatusBaseline ,1 week 1 month,3 months and 6 MonthsPatients will be examined after procedure to check bruising status and will be monitored until it will disappear

Countries

Syria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026